Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 92

    1.

    Exploiting the promiscuity of imatinib.

    Lee SJ, Wang JY.

    J Biol. 2009;8(3):30. Epub 2009 Apr 15. Erratum in: J Biol. 2010;8:82.

    PMID:
    19435483
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).

    Winger JA, Hantschel O, Superti-Furga G, Kuriyan J.

    BMC Struct Biol. 2009 Feb 24;9:7.

    PMID:
    19236722
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

    Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G.

    Blood. 2007 Dec 1;110(12):4055-63. Epub 2007 Aug 24.

    PMID:
    17720881
    [PubMed - indexed for MEDLINE]
    Free Article
    4.

    A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.

    Rix U, Remsing Rix LL, Terker AS, Fernbach NV, Hantschel O, Planyavsky M, Breitwieser FP, Herrmann H, Colinge J, Bennett KL, Augustin M, Till JH, Heinrich MC, Valent P, Superti-Furga G.

    Leukemia. 2010 Jan;24(1):44-50. Epub 2009 Nov 5.

    PMID:
    19890374
    [PubMed - indexed for MEDLINE]
    5.

    Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.

    Jabbour E, Cortes J, Giles F, O'Brien S, Kantarijan H.

    IDrugs. 2007 Jul;10(7):468-79.

    PMID:
    17642017
    [PubMed - indexed for MEDLINE]
    6.

    New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

    O'Hare T, Eide CA, Deininger MW.

    Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. Review.

    PMID:
    18491988
    [PubMed - indexed for MEDLINE]
    7.

    Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.

    Zonder JA, Schiffer CA.

    Curr Hematol Malig Rep. 2006 Sep;1(3):141-51. Review.

    PMID:
    20425345
    [PubMed - indexed for MEDLINE]
    8.

    Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.

    Manley PW, Stiefl N, Cowan-Jacob SW, Kaufman S, Mestan J, Wartmann M, Wiesmann M, Woodman R, Gallagher N.

    Bioorg Med Chem. 2010 Oct 1;18(19):6977-86. Epub 2010 Aug 14.

    PMID:
    20817538
    [PubMed - indexed for MEDLINE]
    9.

    Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.

    Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, Jahnke W, Grzesiek S.

    Biomol NMR Assign. 2008 Jun;2(1):41-2. Epub 2008 Mar 5.

    PMID:
    19636920
    [PubMed - indexed for MEDLINE]
    10.

    Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.

    Bixby D, Talpaz M.

    Hematology Am Soc Hematol Educ Program. 2009:461-76. Review.

    PMID:
    20008232
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.

    Hantschel O, Rix U, Superti-Furga G.

    Leuk Lymphoma. 2008 Apr;49(4):615-9. Review.

    PMID:
    18398720
    [PubMed - indexed for MEDLINE]
    12.

    A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.

    Gumireddy K, Baker SJ, Cosenza SC, John P, Kang AD, Robell KA, Reddy MV, Reddy EP.

    Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1992-7. Epub 2005 Jan 27. Erratum in: Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5635.

    PMID:
    15677719
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

    Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

    Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

    PMID:
    15657179
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

    O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

    Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

    PMID:
    15256422
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

    Breccia M, Alimena G.

    Curr Drug Targets. 2009 Jun;10(6):530-6. Review.

    PMID:
    19519355
    [PubMed - indexed for MEDLINE]
    16.

    Overcoming kinase resistance in chronic myeloid leukemia.

    Lee F, Fandi A, Voi M.

    Int J Biochem Cell Biol. 2008;40(3):334-43. Review.

    PMID:
    18401881
    [PubMed - indexed for MEDLINE]
    18.

    Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.

    Quintás-Cardama A, Kantarjian HM, Cortes JE.

    Cancer Control. 2009 Apr;16(2):122-31. Review.

    PMID:
    19337198
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.

    Nimmanapalli R, O'Bryan E, Huang M, Bali P, Burnette PK, Loughran T, Tepperberg J, Jove R, Bhalla K.

    Cancer Res. 2002 Oct 15;62(20):5761-9.

    PMID:
    12384536
    [PubMed - indexed for MEDLINE]
    Free Article
    20.

    The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

    Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE.

    Cancer Res. 2006 Jun 1;66(11):5790-7.

    PMID:
    16740718
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk